Methysticin is a low-toxicity NF-κB inhibitor with potential therapeutic applications in the prevention and treatment of various diseases associated with NF-κB dysregulation, including cancer, HIV/AIDS, asthma, diabetes, and arthritis; it also induces CYP1A1 enzyme activity, which may influence the metabolism of drugs processed by CYP1A1.